Zymeworks Inc.
Zymeworks Inc. (ZYME) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
zyme · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Zymeworks Inc. (ZYME) measures how much investors pay for each dollar of the company's trailing earnings. ZYME's current PE ratio of N/A is calculated by dividing its stock price of $23.93 by its TTM earnings per share of -$1.37.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2014 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Zymeworks Inc.You ZYME | $1.8B | N/A | — | -$1.37 |
 Ardelyx, Inc. ARDX | $1.4B | N/A | — | -$0.26 |
 BioCryst Pharmaceuticals, Inc. BCRX | $1.8B | 6.20x | — | $1.26 |
 Immunome, Inc. IMNM | $1.8B | N/A | — | -$2.43 |
 Maze Therapeutics, Inc. MAZE | $1.3B | N/A | — | -$3.05 |
 Intellia Therapeutics, Inc. NTLA | $1.5B | N/A | — | -$3.81 |
 Pharvaris N.V. PHVS | $2.2B | N/A | — | -$2.97 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-1.08 | — | |
2024-12-31 FY2024 | — | $-1.62 | — | |
2023-12-31 FY2023 | — | $-1.72 | — | |
2022-12-31 FY2022 | 4.12x | $1.91 | — | |
2021-12-31 FY2021 | — | $-4.06 | — | |
2020-12-31 FY2020 | — | $-3.58 | — | |
2019-12-31 FY2019 | — | $-3.83 | — | |
2018-12-31 FY2018 | — | $-1.26 | — | |
2017-12-31 FY2017 | — | $-0.49 | — | |
2016-12-31 FY2016 | — | $-1.72 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Zymeworks Inc. (ZYME) measures how much investors pay for each dollar of the company's trailing earnings. ZYME's current PE ratio of N/A is calculated by dividing its stock price of $23.93 by its TTM earnings per share of -$1.37.
Frequently asked questions
ZYME pe ratio · 6 questionsZYME's current PE ratio is N/A as of 2026-06-08, based on a stock price of $23.93 and TTM EPS of -$1.37. Data sourced from Financial Modeling Prep via ZYME's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Zymeworks Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08